Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
1.070
-0.050 (-4.46%)
At close: Feb 21, 2025, 4:00 PM
1.090
+0.020 (1.87%)
After-hours: Feb 21, 2025, 7:52 PM EST
Sangamo Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Sangamo Therapeutics stock have an average target of 5.17, with a low estimate of 2.00 and a high estimate of 10. The average target predicts an increase of 383.18% from the current stock price of 1.07.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sangamo Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 3 | 3 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +834.58% | Jan 27, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +367.29% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +834.58% | Jan 2, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $7 → $3 | Strong Buy | Maintains | $7 → $3 | +180.37% | Dec 31, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | +86.92% | Dec 31, 2024 |
Financial Forecast
Revenue This Year
61.70M
from 176.23M
Decreased by -64.99%
Revenue Next Year
53.13M
from 61.70M
Decreased by -13.90%
EPS This Year
-0.48
from -1.48
EPS Next Year
-0.30
from -0.48
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 74.6M | 110.3M | 142.8M | |||
| Avg | 61.7M | 53.1M | 75.3M | |||
| Low | 49.0M | 20.4M | 24.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -57.7% | 78.7% | 168.8% | |||
| Avg | -65.0% | -13.9% | 41.8% | |||
| Low | -72.2% | -67.0% | -54.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.42 | 0.26 | -0.13 |
| Avg | -0.48 | -0.30 | -0.26 |
| Low | -0.53 | -0.59 | -0.57 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.